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Abstract
Complex Regional Pain Syndrome (CRPS) is a persistent pain condition that remains incompletely 
understood and challenging to treat. Historically, a wide range of different outcome measures have 
been used to capture the multidimensional nature of CRPS. This has been a significant limiting 
factor in the advancement of our understanding of the mechanisms and management of CRPS.
In 2013, an international consortium of patients, clinicians, researchers and industry 
representatives was established, to develop and agree on a minimum core set of standardised 
outcome measures for use in future CRPS clinical research, including but not limited to clinical 
trials within adult populations
The development of a core measurement set was informed through workshops and supplementary 
work, using an iterative consensus process. ‘What is the clinical presentation and course of CRPS, 
and what factors influence it?’ was agreed as the most pertinent research question that our 
standardised set of patient-reported outcome measures should be selected to answer. The domains 
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encompassing the key concepts necessary to answer the research question were agreed as: pain, 
disease severity, participation and physical function, emotional and psychological function, self 
efficacy, catastrophizing and patient's global impression of change. The final core measurement set 
included the optimum generic or condition-specific patient-reported questionnaire outcome 
measures, which captured the essence of each domain, and one clinician reported outcome 
measure to capture the degree of severity of CRPS. The next step is to test the feasibility and 
acceptability of collecting outcome measure data using the core measurement set in the CRPS 
population internationally.
1 Introduction
Complex Regional Pain Syndrome (CRPS) is a pain condition, usually affecting a single 
limb, which manifests in a wide range of sensory, motor, trophic and autonomic 
abnormalities [29]. Prospective studies indicate that most cases will resolve within 6-13 
months [4]; however, 15-20% of individuals will develop a long-term disability, negatively 
affecting their quality of life [21,26]. In recent years, revised diagnostic and research criteria 
have been published, resulting in improved standardisation across study participants [29]. 
Currently, however, there is no internationally agreed upon standardised core measurement 
set for CRPS clinical research studies in adult populations. This has limited the synthesis of 
clinical research evidence and consequently impeded the understanding of CRPS and 
potential therapeutic interventions [41,59]. Due to the multidimensional nature of the 
condition, CRPS clinical studies currently use a diverse range of questionnaire outcome 
measures [28]. Furthermore, CRPS has recently been categorised as an ’orphan disease’ by 
the US Food and Drug Administration and the European Medicines Agency, on the basis 
that fewer than 200,000 people in the US, and fewer than 154,000 people in the European 
Union, are affected each year [20,57]. This further highlights the importance of conducting 
multi-centre collaborative projects to help achieve sufficient sample sizes for meaningful 
clinical studies.
The development of a core measurement set would facilitate the pooling and comparison of 
data to answer specific research questions agreed upon as internationally important and 
relevant for the advancement of CRPS treatment. Recommending the use of the core 
measurement set within all clinical research studies would enable these identified research 
questions to be answered in an optimal and timely manner.
A core outcome measurement set can be defined as an agreed upon, standardised set of 
outcomes, which should be measured and reported in all clinical trials in a particular 
condition [61]. In recent years, core measurement sets have been increasingly developed in 
many health conditions in response to the inconsistency of outcome measures used in 
clinical trials investigating the same disease or condition [8,25]. Utilisation of a core 
measurement set would reduce heterogeneity and thereby facilitate the reporting of a 
complete and consistent set of outcome measures across studies [55].
Previous initiatives have advocated the use of core outcome measurement sets in pain and 
rheumatology clinical trials: Initiative on Methods Measurement and Pain Assessment in 
Clinical Trials (IMMPACT) [17] and Outcome Measures in Rheumatology (OMERACT) 
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[24]. This provided a starting point for our work, due to a degree of overlap between these 
disorders and CRPS. The complexity and multifactorial nature of CRPS, however, 
necessitated the development of a core measurement set specific to this condition. 
Furthermore, due to the relatively low incidence of CRPS, we wished to broaden the 
relevance of our core set to encompass all clinical research studies, not exclusive to, but 
including clinical trials, so as to optimise our ability to create large study populations by 
combining multi-centre data sets.
This paper will present the first internationally agreed core measurement set recommended 
for use in CRPS clinical research.
2 Methods
2.1 The consortium
An international consortium was established in 2013, under the auspices, and with the 
support of the International Association for the Study of Pain (IASP) CRPS Special Interest 
Group, to agree upon a minimum core set of outcome measures recommended for use in all 
CRPS clinical studies, including clinical trials. The acronym COMPACT was agreed upon 
and adopted by the consortium to represent the initiative and the resultant core measurement 
set. COMPACT initally represented ‘Core Outcome Measures for complex regional PAin 
syndrome Clinical Trials’. However, through preparation of this manuscript, and Reviewers’ 
feedback, it was agreed by the consortium that as we are recommending this core set as 
appropriate for use in all clinical research studies, not exclusively for trials, then ‘Core 
Outcome Measures for complex regional PAin syndrome Clinical sTudies’ was a more 
appropriate title for this core set.
The consortium comprised CRPS patients, clinicians, researchers and industry 
representatives from fifteen countries: Switzerland, Germany, the Netherlands, Canada, 
United States, Denmark, Norway, Israel, Australia, New Zealand, South Africa, Japan, 
Argentina, Brazil and United Kingdom. Members were recruited from the global CRPS 
community via an email invitation. Members included those with clinical or research 
expertise in CRPS from within an academic or clinical setting and/or an interest in treatment 
outcome measures.
Patient representatives were recruited via support groups representing the UK, Netherlands 
and Switzerland. The inclusion of patient representatives, within our research team, was 
considered essential to ensure the core measurement set included outcome measures that 
were important to those with CRPS and pertinent to their experience of the condition. 
Kirwan et al.(2003) [35] described the value of this and the benefit of seeking a patient’s 
perspective to gain understanding of the terms used within the outcome measures. Patient 
involvement, as active collaborators, contributes to the development of credible patient-
reported outcome measures, which are embedded in the patient experience [51].
Since being established in May 2014, the CRPS International Research Consortium (IRC), 
an organisation facilitating the pooling of resources for timely and conclusive studies 
(www.crpsconsortium.org), has supported COMPACT by encouraging links with other 
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researchers. In addition, researchers wishing to use the core measurement set will be able to 
access it via the IRC, thereby monitoring utilisation and version control.
2.2 Ethical approval and funding
Ethical approval was obtained from the University of the West of England, Bristol, UK. The 
Royal United Hospitals NHS Foundation Trust, Bath, UK provided sponsorship. Funding 
was received from the Balgrist Foundation, Switzerland and the Dutch National CRPS 
Patient Organization.
2.3 Procedure
2.3.1 The workshops—Four workshops (W) (range 15-27 attendees) were convened 
between November 2013 and August 2015.
• W1 was held in November 2013, Bath, UK (n= 27)
• W2 - May 2014, Chicago, USA (n= 15)
• W3 - January 2015, Bath, UK (n= 20)
• W4 - August 2015, Zurich, Switzerland (n= 18)
Invitation to attend the workshops was extended to all members of the consortium, however 
attendance was limited by geographical location and availability of funding to attend (see 
supplementary information for list of attendees). The opportunity to contribute to 
supplementary work via email was open to all members. The COMPACT initiative was 
presented at the 15th World Congress of Pain in Buenos Aires in 2014 and to members of the 
International Association of the Study of Pain (IASP) CRPS Special Interest Group via 
regular newsletters. In keeping with recommendations for incorporating stakeholder input, 
Workshop 1 and 3 included representatives from the pharmaceutical industry, with specific 
expertise in chronic pain and clinical rheumatology trials [51]. The representation was from 
Grunenthal Ltd* (W1&3) and Pfizer Ltd (W1) recruited via an email invitation sent to 
industries working in the area of CRPS or pain.
The four workshops followed a semi-structured format, (see supplementary information). 
Two of the authors (SG, CM) chaired the workshops and/or led discussions. Each workshop, 
by its nature, included scheduled timeframes, where attendees worked in small groups with a 
clear scope and goal. Group work was fed back to all attendees for further discussion. All 
decisions were agreed upon by majority consensus of those present at each workshop. 
Figure 1 depicts the development process.
2.3.2 The research question—Prior to W1, consortium members were asked to 
identify research questions they wished to address to advance the treatment of CRPS. For 
example, these could be in relation to the identification of risk factors for the development 
of, or the clinical course of the condition, both of which are yet to be firmly established in 
CRPS [58]. The first COMPACT workshop identified a research question which required 
*Opinions and views expressed by the representative from Grunenthal Ltd, were given as individual opinions, as an experienced 
employee within pharmaceutical industry, and not necessarily representative of Grunenthal Ltd as a whole.”
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international collaboration and pooling of data, and could not be investigated without a 
consistent data set. It was agreed the research question should cover three main purposes for 
measurement: classification (disease/no disease), effectiveness (change over time) and 
prognostic indicators.
The initial research question was agreed as:
‘What is the clinical presentation and course of CRPS and what factors influence 
it?’
Answering this question, will provide a better understanding of the potential phenotypes of 
CRPS, prognostic indicators, and methods of targeting therapeutic approaches. It is relevant 
within the context of both cross sectional and prospective studies, including cohort studies 
and comparative clinical trials. The question encompasses type 1 and type 2 CRPS, and is 
relevant across the disease trajectory.
2.3.3 Domains—The minimum number of domains, or key concepts, which were 
considered necessary to answer the research question, was agreed upon by consensus. These 
provided a framework or scope which then informed the selection of appropriate 
questionnaire outcome measures or instruments.The OMERACT and IMMPACT initiatives 
were presented at W1 identifying a number of core domains which should be considered 
when establishing a core set of health outcome measures [8,55]. A decision was made to use 
the IMMPACT core domains as a starting point, as these are recommended for chronic pain 
clinical trials [55] and are therefore highly applicable to CRPS, a chronic pain condition. 
However, in order to develop a robust core measurement set, a decision was made not to 
adopt these without confirming their applicability to CRPS, a condition somewhat unique in 
its features and life impacts. Both IMMPACT and OMERACT recommend particular 
domains which should be considered in condition-specific clinical trials [8,55]. The domains 
should be appropriate for the population under investigation, measure positive and negative 
outcomes and match the purpose of the clinical trial [55]. With this in mind, the consortium 
chose to identify CRPS specific domains rather than directly adopt those previously 
identified for generic chronic pain or rheumatology studies.
2.3.4 Measurement tools—Selection of questionnaire outcome measures was agreed 
by consensus and informed by: 1) a systematic literature review conducted by members of 
the consortium [28], 2) a core data set used by a pre-existing Dutch clinical and academic 
CRPS research consortium (TREND), and 3) patient burden. The heterogeneity of outcome 
measures, which was apparent from the systematic review [28], demonstrated the challenge 
of synthesising research evidence at an international level and even nationally. Emphasis was 
placed on identifying the minimum number of outcome measures (and the briefest possible), 
which would permit reliable assessment of the core domains, as the intention is for 
individual researchers to augment the core measurement set with measures specific to their 
investigation. A number of different questionnaires were considered for inclusion in the core 
measurement set (see supplementary information), many of which were identified from the 
systematic literature review [28]. A questionnaire was considered based on its ability to 
capture the key aspects of each domain, its length and experience of its use by the workshop 
attendees.
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Consideration was given to the development of new instruments, however, due to the time 
and resource required for this, existing instruments were first examined for suitability. A 
systematic review of the literature, which evaluated the psychometric properties of outcome 
measures used for CRPS, found no tool to have been fully assessed in this population [44], 
and no specific tool was recommended for use in CRPS [44]. This is based on prior CRPS 
specific validation, with the exception of the CRPS Severity Score [30].
In addition to hard copy questionnaire outcome measures, including those identified as a 
result of the literature review, consideration was also given to an electronic patient-reported 
outcome measurement information system (see 2.3.5).
The measures agreed upon at W4 primarily comprised patient-reported outcome measures 
(PROMs), measuring various aspects of health and function identified as important to the 
CRPS patient and applicable to the research question. The only addition to these PROMs 
was a clinican reported outcome measure to describe the severity of the condition. In the 
interests of time and resources, the consortium did not conduct a review of objective clinical 
outcome measures, for example thermal imaging to record temperature change or volumetric 
data to measure oedema, though we recognise the important contribution of these types of 
measures in CRPS clinical research. This work is planned to be conducted in the near future 
under the auspices of the IRC and IASP CRPS Special Interest Group.
2.3.5 Patient-Reported Outcomes Measurement Information System 
(PROMIS®)—W2 and W3 considered the potential of using an existing item bank of 
patient reported outcome measures: Patient-Reported Outcomes Measurement Information 
System (PROMIS) [13]. This is a National Institute of Health (USA) funded system, which 
provides psychometrically sound and validated patient-reported outcome measures that can 
be used in a wide range of chronic conditions. PROMIS is comprised of calibrated item 
banks to measure diverse health concepts such as pain, physical function and depression; 
these are presented for each domain as individual items and/or instruments of various 
lengths. In addition, PROMIS includes several collections of items, termed profiles, which 
measure multiple domains. For example, the PROMIS-29 profile assesses 7 domains, each 
with 4 questions; depression, anxiety, physical function, pain interference, fatigue, sleep 
disturbance, and ability to participate in social roles and activities [13]. There is also an 
additional numeric pain intensity 0-10 rating scale (NPRS).
The PROSETTA Stone initiative [14] has enabled results obtained using PROMIS items to 
be directly compared with many standard instruments currently employed in clinical trials, 
such as the SF-36 or Brief Pain Inventory. Data collection using the PROMIS item bank can 
be captured electronically on a secure server or alternatively using a paper version. 
Importantly, all instruments are freely available in the public domain and work is underway 
for translation and cultural validation of the profiles in multiple languages.
2.3.6 Modelling of the Core Measurement Set (COMPACT)—To inform 
COMPACT, three models, comprising standard patient-reported outcome measures, were 
constructed and disseminated electronically, for consideration by the consortium. The three 
models were presented at the meeting of the IASP CRPS Special Interest Group in Buenos 
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Aires in 2014. Feedback was collated and presented at W3. Following consultation with 
colleagues familiar with PROMIS, a fourth model was constructed which consisted largely 
of PROMIS items. Feedback was collected from individuals with CRPS (n=5) regarding the 
patient burden and ease of understanding and completion of the various questionnaire 
models. These individuals were naïve to the development of the questionnaire, were not 
members of the consortium and were native English speakers. All four models and the 
patient feedback were presented at W3.
After W3, the final draft COMPACT was presented to a UK based focus group of patient 
researchers (n=3). The design of the document was reviewed in detail on two occasions, to 
allow revisions to be considered and then the feedback was presented to the consortium at 
W4. Care was taken to assess the COMPACT measures for cultural and gender sensitivity, 
for example, ‘gardening’ was given as an alternative to ‘yard work’ and the date within the 
document was internationally formatted. The final COMPACT was agreed upon by 
consensus at W4.
3 Results
3.1 Core Outcome Measures for complex regional PAin syndrome Clinical sTudies 
(COMPACT)
The following outcome measures comprise COMPACT (Table 1). The domains reported in 
Table 1, closely reflect those recommended by IMMPACT [55], with the addition of disease 
severity, catastrophizing and self-efficacy. The outcome measures comprising COMPACT 
are introduced throughout the document with text designed to ensure the respondent focuses 
on only those factors relevant to CRPS. For example, ‘the following questions ask you about 
the type of pain you experience due to CRPS’. Respondents are asked to reflect on a specific 
time frame, for example ‘in the past 7 days.’
3.1.1 Pain—Pain is an overarching feature of CRPS [37] and consequently should be 
assessed in any CRPS clinical study. A recent, international Delphi study (n=252), which 
asked people with CRPS to define their top five priorities for recovery supported this, 
identifying the top two priorities as no further CRPS related pain in their limb(s) and no 
generalised pain [38]. The dimensions of pain intensity and pain interference were 
considered essential for inclusion in the core measurement set in order to distinguish 
between potential sub-types of the condition. Pain intensity is most commonly used as the 
primary outcome measure for studies investigating chronic pain interventions [17]. When 
comparison is made between multiple pain ratings and a single pain rating, the latter has 
been demonstrated to be an accurate predictor of average pain for those with CRPS type 1 
[22]. The authors therefore recommend CRPS pain be rated as the average over the last 
seven days using an item from the PROMIS 29 profile, version 2.0 [13]. A numeric rating 
scale will be used to measure the least and worst pain in the previous 24 hours, to capture 
the daily variability in its intensity. Pain interference will be measured using the four items 
within the PROMIS 29 profile, version 2.0 [13].
There is evidence that pain qualities (eg., burning, cramping, throbbing pain) do change over 
the course of CRPS [49] and therefore capturing the nature of pain qualities was also 
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considered important with regard to identifying potential CRPS sub-types and assessing the 
variability of pain over time. Treatment interventions may be more effective for some pain 
qualities [17]. Pain qualities will be captured using the neuropathic items from the McGill 
Pain Questionnaire-2 (SF-MPQ-2) [18]. Permission was obtained from the author, to 
administer the six quality measures in isolation from the full version of the SF-MPQ-2. A 
number of questionnaire outcome measures were considered to capture this aspect of pain 
(see Table 1) however, the six SF-MPQ-2 neuropathic items capture the essential qualities 
with minimum patient burden. A preliminary Rasch analysis supported the use of this sub-
scale as a ‘stand-alone’ assessment [42] however, this needs to be repeated in a larger, mixed 
population.
Research shows that some people with CRPS experience widespread pain [7], which could 
confound the assessment of CRPS related pain. For this reason, the individual will be asked 
to consider and report only the pain related to the CRPS when completing the instrument. 
The consortium patient researchers recommended the pain measurement tools should not be 
listed first within the COMPACT questionnaire set. This was judged to have the potential to 
place excessive focus on the pain and the negative connotations associated with this.
3.1.2 Disease severity score—Disease severity, measured using the CRPS Severity 
Score (CSS) [30], is completed by the clinician at baseline. The CSS is directly derived from 
the Budapest CRPS diagnostic criteria and will confirm the CRPS diagnosis [29]. Any 
clinician can complete the CSS and no special training is required. In addition it will provide 
information regarding differences in clinical presentation between individuals [10,16] and 
the investigation of possible subtypes of the condition. Symptoms reported by the individual 
and CRPS signs present on examination, are recorded by the clinician. Higher scores 
indicate greater CRPS severity (range 0-16) [31]. In addition to baseline, completion of the 
CSS at a minimum of one of the additional time points of 3, 6 and 12 months are 
recommended if possible. Completion on more than one occasion will enable the changing 
clinical aspects of CRPS over time to be captured for each individual. The CSS has been 
found to be responsive (Effect Size 1.99 [95% Confidence Interval 1.54-2.44], Standardized 
Response Mean =1.42) in a sample of n=66 persons with CRPS followed for one year [43].
3.1.3 Participation and Physical Function—Reduced function as a consequence of 
pain is apparent in individuals with CRPS [6]. Of these, approximately 15% will report 
unremitting pain and physical impairment two years after the onset of CRPS [21,48]. This is 
supported by a recent systematic review, which found functional impairments such as 
weakness, stiffness and limited range of motion persisted in the majority of patients for one 
year or more in varying severity [4].
Social participation was considered important to measure; both in relation to the limitations 
which may result from physical impairment but also social avoidance in order to prevent any 
accidental contact with the affected limb [47]. COMPACT will capture measures of physical 
function and social participation within the PROMIS 29 profile and the EQ-5D-5L, the latter 
used widely, allowing comparison across chronic conditions. The PROMIS 29 profile will 
also measure the constructs of fatigue and sleep quality, which may develop as a 
consequence of living with chronic pain [27]. Once again, the individual will be asked to 
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consider and report how CRPS impacts on their life when completing the instrument, to 
reduce possible confounders related to comorbidities.
3.1.4 Emotional and Psychological Function—As a consequence of living with a 
long-term pain condition, psychological symptoms such as depression and anxiety may 
develop [27]. Although a systematic review identified no relationship between onset of 
CRPS type 1 and several psychological factors [5], some evidence suggests the intensity of 
CRPS pain may be uniquely impacted by psychological distress [3,9,11]. Patients with co-
morbid chronic pain, depression and anxiety have been shown to have worse clinical 
outcomes than patients with pain alone [1,12]. This domain measures anxiety and depression 
using the PROMIS-29 profile. In addition, suicidal ideation will be assessed using a 
PROMIS item [36,45].
3.1.5 Self-efficacy—The Pain Self Efficacy Questionnaire (PSEQ) will be used to 
capture this domain [40]. The respondent considers how confident they are performing each 
activity, while taking their pain into account. This provides more clinically useful data than 
asking about performing an activity in isolation [40].
3.1.6 Catastrophizing—Pain catastrophizing was considered an important dimension of 
the core measurement set. Multiple studies in non-CRPS populations indicate 
catastrophizing is a prospective predictor of negative pain outcomes [19,23,46,50,54]. The 
authors recommend the Pain Catastrophizing Scale (PCS) be used to capture this domain 
[53]: a score of greater than 30 is thought to represent a problematic level of catastrophic 
thinking [52]. Bean et al. [2] reported the average PCS score at baseline was 22.0 in their 
sample of 66 persons diagnosed with CRPS within the previous 12 weeks, but underwent 
significant reduction to a mean score of 13.4 by 6 months as treatment progressed (p<0.001). 
This supports pain catastrophization as an important construct for measuring the evolution of 
this syndrome.
3.1.7 Patients Global Impression of Change—In order to establish the efficacy of 
interventions in CRPS clinical studies it was considered important to capture the patient's 
global impression of change. Respondents will be asked to rate the improvement of CRPS 
using a 7 point scale, ranging from “very much improved” to “very much worse” [33].
3.1.8 Demographic data and healthcare utilisation—COMPACT will include 
demographic data to capture the characteristics of the population such as gender, age, 
affected limb(s) and disease duration. Ability to participate in paid or unpaid employment 
and education will also be reported.
Health care utilisation was excluded from the final domains as it was considered more 
appropriate that individual countries adopt a local measure due to the variation in healthcare 
service systems. Reporting these data may also be affected by an individual’s ability to recall 
clinical interactions and may be influenced by litigious processes in some countries. Use of a 
country specific measure will more appropriately accommodate these cultural variations 
than a single generic tool.
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4 Discussion
The international application of COMPACT will require availability in a wide range of 
languages. This was a consideration throughout the development process and informed the 
final selection of the outcome measures. Many of the selected measures are currently 
available in a number of translations, for example, the EQ-5D-5L [32] and Pain 
Catastrophizing Scale [53]. The PROMIS initiative has addressed translation and cultural 
validation for many of the PROMIS items, although further work is required for translation 
of the full range of languages required for COMPACT. Where documents require translation 
these will be undertaken by the COMPACT consortium research partners in each country 
under strict adherence to the requirements specified by the developers of each questionnaire 
or by adhering to the ‘best practice’ translation standards established in a protocol for the 
CRPS Recovery Study [39]. This uses a forwards and backwards translation approach to 
ensure the meaning of text is the same across each of the countries.
Whilst the measurement properties of the PROMIS tools are assumed to be invariant across 
populations [13], the proposed constellation of outcome measures included in COMPACT 
will require further work to ascertain their psychometric properties and develop relevant 
norms for the CRPS population. This will be undertaken after the feasibility and 
acceptability of COMPACT has been tested using data and views from the international 
CRPS community.
Future work will also include the development and validation of a paediatric version of 
COMPACT. The current version is designed for use in an adult population, although some of 
the measures have already been validated in children or have paediatric versions [15,60].
The authors recognise the importance of developing safe and effective data systems to 
support this work. The consortium will explore the feasibility of using an existing data 
management system for the central collection and management of the COMPACT data. This 
will facilitate data sharing, meta-analysis and will allow sub-group analyses, for example, 
gender-based differences and CRPS subtypes.
The authors recommend COMPACT to be completed by all patients at two time points, 
baseline and 6 months. At 3 months our patient population may have only just initiated 
treatment and rehabilitation, and a recent study demonstrated the greatest change in 
symptom severity was in the first 6 months following CRPS onset [2]. Draft guidance for 
studies evaluating analgesia in chronic pain recommend a study duration of at least 3 months 
[56]. Additional assessment at 3 and/or 12 months are optional, and the CSS should be 
completed at baseline as a minimum. These time points were considered appropriate for our 
specifc research question however, we recognise that these recommended time points may 
need adjusting, or adding to, to meet study specifc requirements.
A key challenge will be to raise awareness and dissemination of the core measurement set to 
promote its use by those conducting CRPS clinical studies. Kirkham et al. (2013) [34] 
identified that 60-70% of rheumatology clinical trials were reporting the full OMERACT 
core measurement set 20 years after its introduction. Future work will include a survey of 
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health professionals within the international CRPS community to identify which outcome 
measures are currently being used and then to re-evaluate this after dissemination.
5 Conclusion
A core measurement set for CRPS clinical studies has been agreed upon by an iterative 
process of consensus. This will facilitate international collaborative studies to advance our 
knowledge and treatment of CRPS. The next step is to test the feasibility and acceptability of 
COMPACT in the international CRPS population, and to identify an appropriate electronic 
data management system. A workshop will be convened in 2018 to review data collected 
from studies using COMPACT, and users (patient and researchers) experience of 
COMPACT.
If researchers outside the COMPACT consortium wish to use COMPACT it can be accessed 
from relevant websites (eg. CRPS International Research Consortium, IASP CRPS Special 
Interest Group). It is asked that, if COMPACT is included in research studies, feedback is 
shared with the COMPACT consortium.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Development of a core measurement set for CRPS clinical research studies
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Table 1
Patient-reported outcome measures included in COMPACT
Domain Outcome Measure Construct
Participant characteristics Gender, affected limb, limb dominance prior to CRPS, 
CRPS duration, participation in employment/education/
voluntary work
Demographic data
Pain Numeric Rating Scale and PROMIS 29 Profile (version 2)
[13]
Pain intensity: average, worst, least
Short-form McGill Pain Questionnaire SF-MPQ-2 [18] Six neuropathic pain items
PROMIS 29 Profile (version 2) [13] Pain interference.
EQ-5D-5L [32] Health state comprising mobility, self 
care, usual activities, pain/discomfort, 
anxiety/depression.
Disease severity CRPS Severity Score [30] Severity of CRPS
CRPS symptom questions Experience of CRPS
Participation and physical function. PROMIS 29 Profile (version 2) Physical function, social participation
EQ-5D- 5L See above
Emotional and psychological function PROMIS 29 Profile (version 2) Anxiety, depression, fatigue, sleep
PROMIS suicidal ideation question [45] Suicidal ideation
EQ-5D- 5L See above
Catastrophizing Pain Catastrophizing Scale [53] Pain catastrophizing
Self efficacy Pain Self-efficacy Questionnaire [40] Self-efficacy
Patient's global impression of change Patient Global Impression of Change# Change in CRPS from baseline
#
To be completed at T2 only
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